Interventional technology developer Cordis, a Johnson & Johnson subsidiary, has received CE Mark approval to market its Cypher Select sirolimus-eluting coronary stent in all member states of the European Union (EU), European Economic Area (EEA), and Switzerland.
Approval of the device, which is used for the treatment of in-stent restenosis in patients with coronary artery disease, is an expansion of the approval previously granted to the firm's Cypher sirolimus-eluting coronary stent, which received the CE Mark last February, according to Cordis of Warren, NJ.
By AuntMinnie.com staff writersApril 8, 2004
Related Reading
Guidant, Johnson & Johnson ink stent deal, February 27, 2004
Cordis stent gets FDA OK, September 5, 2003
Cordis files suit against Boston Scientific, January 15, 2003
Cordis debuts new biliary stent, August 27, 2002
Copyright © 2004 AuntMinnie.com
